Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://journals.lww.com/hep/fulltext/2023/05000/the_liver_cancer_immune_microenvironment_.30.aspx, but it redirected us to https://journals.lww.com/hep/fulltext/2023/05000/the_liver_cancer_immune_microenvironment_.30.aspx. The analysis below is for the second page.

Title[redir]:
Hepatology
Description:
e patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib, as a first‐line therapy. In the last few years, immune‐checkpoint inhibitors (ICIs) have revolutionized cancer therapy and have gained an increased interest in the treatment of HCC. In 2020, the combination of atezolizumab (anti‐programmed death‐ligand 1) and bevacizumab (anti–vascular endothelial growth factor) improved overall survival over sorafenib, resulting in Food and Drug Administration (FDA) approval as a first‐line treatment for patients with advanced HCC. Despite these major advances, a better molecular and cellular characterization of the tumor microenvironment is still needed because it has a crucial role in the development and progression of HCC. Inflamed (hot) and noninflamed (cold) HCC tumors and genomic signatures have been associated with response to ICIs. However, there are no additional biomarkers to guide clinical decision‐making. Other immune‐targeting strategies, such as adoptive T‐cell transfer, vaccination, and virotherapy, are currently under development. This review provides an overview on the HCC immune microenvironment, different cellular players, current available immunotherapies, and potential immunotherapy modalities....

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is doi.org built with?


Doi.org relies on MYBB.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌍 Impressive Traffic: 500k - 1M visitors per month


Based on our best estimate, this website will receive around 600,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't see how the site brings in money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

cells, hcc, cell, tumor, patients, liver, cancer, expression, immune, tumors, monocytes, activation, growth, figure, macrophages, survival, dcs, clinical, sorafenib, combination, pdl, antitumor, treatment, tme, ccl, shown, high, tgfβ, mice, immunosuppressive, human, tams, advanced, progression, potential, tans, recruitment, factor, role, activity, nct, cytokines, therapies, receptor, targeting, blood, pathway, neutrophils, promote, recently,

Topics {✒️}

mir‐146a‐5p–embedded exosomes secreted pmn‐mdsc‐cd11b+cd33+hla‐dr− ctnnb1‐mutated subclasses g5–g6 granulocyte‐macrophage colony‐stimulating factor high ccrk/il‐6/cd11b/cd33 expression chimeric receptor nkg2d‐cd3ζ‐dap10 gut–microbiota–liver axis represents hif1a/nf‐κb/cxcl5 pathway gpc3+asgr1+hcc xenograft models circulating cd14+hla‐drhigh monocytes dc‐mediated antigen cross‐presentation anti‐pd‐l1 showed reduced advanced tumor‐node‐metastasis stage tlr9/nf‐κb pathway raf–mek–erk cascade hcc‐bearing mouse model induce cd4+cd25+foxp3+ tregs mir‐301b‐3p expression yolk sac–derived precursors guide clinical decision‐making antibody‐dependent cellular cytotoxicity patient tumor‐node‐metastasis stages cd33+cd‐11b+‐mdscs tumor‐surrounding fibrotic livers humanized anti‐nkg2a antibody costimulatory molecule icosl‐41bb219 wnt/β‐catenin pathway immunodeficient tumor‐bearing mice anti‐programmed death‐ligand 1 igd−igg+cd27−cd38− high‐fat diet tissue‐draining lymph nodes120 peritumoral cd86+hla‐dr+ monocytes csf‐1r inhibitor plx3397 inhibitory immune‐checkpoint receptors affecting cell‐cycle control tumor‐bearing immunocompromised mice nk‐mediated therapeutic strategies long‐term side effects anti–il‐6 antibody siltuximab met/csf1r/src inhibitor aasld practice guideline castration‐resistant prostate cancer single‐cell rna sequencing inhibitory immune‐checkpoint ligands lower disease‐free survival sdf1a/cxcr4/il‐6 pathway interferon γ [ifn‐γ] nk‐based cik therapies gut‐derived microbial metabolites

Questions {❓}

  • AASLD Member?
  • FIGURE 2: Neutrophils: friends or foes?
  • NEUTROPHILS: FRIENDS OR FOES?

External Links {🔗}(359)

Analytics and Tracking {📊}

  • Comscore
  • Google Analytics
  • Google Tag Manager
  • Mouseflow

Libraries {📚}

  • Bootstrap
  • FontAwesome
  • jQuery
  • Video.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Cookielaw
  • Jsdelivr
  • Mouseflow
  • Scite
  • Wolterskluwer

5.3s.